A recent study looked at the economics of MEAs
to determine if these arrangements are beneficial to payers from an economic welfare
perspective with reference to the UK (Barros 2011). The study concluded that the overall
welfare effects of these schemes are ambiguous because more patients than necessary may
be treated and because manufacturers, anticipating such agreements, are likely to raise
prices and therefore caution against their use was urged